ELISpot and Fluorospot Assay Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 13.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
ELISpot and Fluorospot Assay Market Analysis
The ELISpot and FluoroSpot assay market is expected to register a CAGR of 13.3% during the forecast period.
- The COVID-19 pandemic significantly impacted healthcare systems worldwide, including the ELISpot and FluoroSpot assay markets. A 2020 article by Medtech suggested a link between antibody titers and T-cell responsiveness in COVID-19. The strongest T-cell response was observed in three individuals (C4, C5, and C7), with the lowest antibody response in COVID-19 patients, as measured by the FluoroSpot assay. ELISpot and FluoroSpot assays are commonly used to assess SARS-CoV-2-specific T- and B-cell immunity in COVID-19 patients. However, since COVID-19 cases declined last year, the market has reported a slight decline. Nevertheless, the market is expected to show a stable growth rate during the forecast period.
- The ELISpot and FluoroSpot assay market is expected to grow due to several factors. Firstly, rising vaccine research to tackle drug-resistant strains, the growing global occurrence of chronic illnesses, and technological innovations in ELISpot and FluoroSpot analyzers and assay kits are expected to drive market growth. ELISpot is a critical tool in vaccine development for various illnesses, including acquired immunodeficiency syndrome (AIDS), tuberculosis, malaria, cancer, and flu. The ELISpot test is widely utilized in clinical studies to evaluate vaccines. In a June 2021 article published in BMC Infectious Diseases Journal, the FluoroSpot assay based on the ELISpot was more accurate than enzyme-linked immunoassay (ELISA) or flow cytometry (FCM). Therefore, these assays are given priority to ensure precision in research diagnostics.
- The prevalence of chronic diseases is also expected to boost the market growth of ELISpot and FluoroSpot assays. According to the Canadian Cancer Statistics November 2021 report, an estimated 2 in 5 Canadians were likely to be diagnosed with cancer in their lifetime. An estimated 229,200 Canadians are predicted to have been diagnosed with cancer in 2021. Furthermore, non-communicable diseases (NCDs) kill 41 million people globally each year, equivalent to 71% of all deaths, according to an April 2021 update by the World Health Organization (WHO). More than 15 million people die from NCDs between the ages of 30 and 69 years, with 85% of these premature deaths occurring in low- and middle-income countries. Consequently, the increasing prevalence of chronic diseases is expected to increase the utility of ELISpot and FluroSpot assays for diagnosis purposes, propelling the market growth.
- The strategic initiatives adopted by key players, such as product launches, approvals, partnerships, and research studies, are also expected to drive market growth. For instance, in April 2021, Ardigen and ImmuMap launched a research collaboration focused on identifying T-cell receptors (TCRs) reactive to tumor-associated neoantigens. The collaboration involves ELISpot assays, next-generation sequencing (NGS), MHC multimer labeling and sorting, and 10x Genomics Single Cell Immune Profiling. Such developments are expected to spur innovation in the assays and ultimately augment market growth.
- In conclusion, the ELISpot and FluoroSpot market is expected to witness tremendous growth over the forecast period due to factors such as the rising prevalence of chronic diseases and technological advancements by key players. However, the availability of alternative detection technologies is likely to impede market growth.
ELISpot and Fluorospot Assay Market Trends
Assay Kits is Expected to Hold the Largest Market Share in the ELISpot and FluoroSpot Assay Market
- Assay kits play a vital role in a wide range of applications in life science research, drug development, and environmental monitoring. These applications include researching disease pathways, screening for prospective drug candidates, and evaluating biopharmaceutical production processes. The assay kits segment retains a dominant share owing to factors such as the high incidence of chronic ailments and increased use of these products for vaccine development in clinical studies.
- According to the American Society of Clinical Oncology's 2022 report, the United States witnessed an estimated 3,610 new cases of bone cancer and 2,060 deaths due to bone cancer in 2021. The prevalence of bone cancer and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, and other conditions is estimated to drive the segment's growth as they are used in diagnosing these diseases.
- Moreover, the utility of assay kits in research activities and innovation in ELISpot assay kits is also expected to drive segment growth during the forecast period. For instance, a research study published in the Vaccines (Basel) Journal in December 2021 used an interferon-γ ELISpot assay on 38 kidney transplant recipients to detect serotype-specific cellular responses against S. pneumonia. Thus, the wide use of assays for research studies and clinical trials boosts the assay kit segment during the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
- Due to several factors, North America is expected to dominate the ELISpot and FluoroSpot assay market throughout the forecast period. Firstly, there is a rising prevalence of cancer and infectious disease disorders in the region. The American Cancer Society's Cancer Statistics 2022 predicted that there would be 1,918,030 new cancer cases in the United States in 2022, including breast cancer, leukemia, and lymphoma.
- Moreover, data published by the American Academy of Pediatrics in March 2022 revealed that more than one million people in the United States have long-term hepatitis B infections, which can lead to chronic conditions such as liver cancer. This is expected to increase the demand for vaccines and drive the growth of ELISPOT assay, which is highly useful in studying infectious diseases.
- Secondly, technological advancements in test kits and analyzers for ELISpot and FluoroSpot are also contributing to the market growth. In September 2021, ImmunoSpot released SpotStat Software for statistical analysis of ELISPOT/FluoroSpot data. This software provides statistically validated differentiation between antigen-induced and negative controls, improving the accuracy of test results.
- Given these factors, the growth of the ELISpot and FluoroSpot assay market is anticipated in the North American region.
ELISpot and Fluorospot Assay Industry Overview
The ELISpot and FluoroSpot assay market is consolidated and dominated by a few major players. These key players hold the largest market share and are actively acquiring other companies and launching new products to strengthen their global market positions. Prominent players in this market include Becton, Dickinson and Company, U-Cytech Biosciences, Cellular Technologies Limited, Mabtech AB, Abcam, Autoimmun Diagnostika GmbH, Lophius Biosciences GmbH, Bio-Connect B.V., Oxford Immunotec, and Bio-Techne Corporation.
ELISpot and Fluorospot Assay Market Leaders
-
Becton, Dickinson and Company
-
U-CyTech biosciences
-
Cellular Technologies Limited (CTL)
-
Mabtech AB
-
Abcam
*Disclaimer: Major Players sorted in no particular order
ELISpot and Fluorospot Assay Market News
- June 2022: BD and CerTest Biotec collaborated to create a molecular diagnostic test for the Monkeypox virus, a rare disease caused by a virus closely related to the smallpox virus. The collaboration aims to improve the diagnosis and management of Monkeypox infections. As part of the collaboration, the assay will leverage the BD MAX™ open system reagent suite to validate the CerTest VIASURE Monkeypox CE/IVD molecular test on the BD MAX™ System. The assay will be available for BD MAX™ users and may help advance understanding of the global spread of the disease.
- April 2022: ProImmune Ltd. launched a B-cell ELISpot assay service. The B cell ELISpot assay is a method used to analyze the immune response of B cells, which play a critical role in the body's immune defense against infections, immunological modulators, vaccines, and therapeutic drugs. Researchers can assess the efficacy of vaccines or the potency of therapeutic drugs by measuring the number of B cells producing a specific antibody in response to a particular stimulus.
ELISpot and Fluorospot Assay Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Incidence of Chronic Diseases
- 4.2.2 Technological Breakthroughs in Test Kits and analyzers for ELISpot and FluoroSpot
-
4.3 Market Restraints
- 4.3.1 Availability of alternative detection technologies
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Product
- 5.1.1 Analyzers
- 5.1.2 Assay kits
- 5.1.3 Ancillary Products
-
5.2 By End-User
- 5.2.1 Hospitals & Clinical labs
- 5.2.2 Biopharmaceutical Company
- 5.2.3 Research Institutes
-
5.3 By Application
- 5.3.1 Research
- 5.3.1.1 Vaccine Development
- 5.3.1.2 Clinical Trials
- 5.3.1.3 Cancer Research
- 5.3.2 Diagnostics
- 5.3.2.1 Infectious Disease
- 5.3.2.2 Transplants
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Becton, Dickinson and Company
- 6.1.2 U-Cytech Biosciences
- 6.1.3 Cellular Technologies Limited
- 6.1.4 Mabtech AB
- 6.1.5 Abcam
- 6.1.6 Autoimmun Diagnostika GmbH
- 6.1.7 Lophius Biosciences GmbH
- 6.1.8 Bio-Connect B.V.
- 6.1.9 Oxford Immunotec
- 6.1.10 Bio-Techne Corporation
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityELISpot and Fluorospot Assay Industry Segmentation
As per the scope of the report, FluroSpot and ELISpot are commonly used with fluorophores marked detection reagents for the realistic analysis of the immune system at the single-cell level. The FluoroSpot assay integrates ELISpot's sensitivity with the ability to concurrently analyze multi-analyte secretion, allowing cell population studies with different operational characteristics.
The ELISpot and FluoroSpot assay market is segmented by product (analyzers, assay kits, and ancillary products), application (research (vaccine development, clinical trials, and cancer research), and diagnostics (infectious disease and transplants)), end user (hospitals & clinical labs, biopharmaceutical companies, and research institutes), and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD million) for the above segments.
| By Product | Analyzers | |
| Assay kits | ||
| Ancillary Products | ||
| By End-User | Hospitals & Clinical labs | |
| Biopharmaceutical Company | ||
| Research Institutes | ||
| By Application | Research | Vaccine Development |
| Clinical Trials | ||
| Cancer Research | ||
| By Application | Diagnostics | Infectious Disease |
| Transplants | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
ELISpot and Fluorospot Assay Market Research FAQs
What is the current ELISpot And FluoroSpot Assay Market size?
The ELISpot And FluoroSpot Assay Market is projected to register a CAGR of 13.30% during the forecast period (2024-2029)
Who are the key players in ELISpot And FluoroSpot Assay Market?
Becton, Dickinson and Company, U-CyTech biosciences, Cellular Technologies Limited (CTL), Mabtech AB and Abcam are the major companies operating in the ELISpot And FluoroSpot Assay Market.
Which is the fastest growing region in ELISpot And FluoroSpot Assay Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in ELISpot And FluoroSpot Assay Market?
In 2024, the North America accounts for the largest market share in ELISpot And FluoroSpot Assay Market.
What years does this ELISpot And FluoroSpot Assay Market cover?
The report covers the ELISpot And FluoroSpot Assay Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the ELISpot And FluoroSpot Assay Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
ELISpot and Fluorospot Assay Industry Report
Statistics for the 2024 ELISpot and Fluorospot Assay market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. ELISpot and Fluorospot Assay analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
